Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Change in Accured Expenses (2016 - 2025)

Cytokinetics (CYTK) has disclosed Change in Accured Expenses for 16 consecutive years, with $29.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses changed N/A to $29.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.8 million, a N/A change, with the full-year FY2025 number at $33.6 million, up 136.94% from a year prior.
  • Change in Accured Expenses was $29.5 million for Q4 2025 at Cytokinetics, up from -$14.4 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $32.1 million in Q4 2023 to a low of -$14.4 million in Q1 2025.
  • A 5-year average of $3.7 million and a median of $4.2 million in 2023 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 9253.56% in 2023; the steepest drop was 287.96% in 2023.
  • Cytokinetics' Change in Accured Expenses stood at $1.2 million in 2021, then plummeted by 128.33% to -$351000.0 in 2022, then surged by 9253.56% to $32.1 million in 2023, then plummeted by 82.85% to $5.5 million in 2024, then skyrocketed by 435.26% to $29.5 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Change in Accured Expenses are $29.5 million (Q4 2025), -$14.4 million (Q1 2025), and $5.5 million (Q3 2024).